Outcomes among racial and ethnic minority patients with advanced cancers in phase 1 trials: a meta-analysis (vol 7, e2421485, 2024)

被引：0
|
作者：
Goel, Sanjay
Negassa, Abdissa
Ghalib, Mohammad H.
Chaudhary, Imran
Desai, Kavita
Shah, Umang
Swami, Umang
Cohen, Bruce
Maitra, Radhashree
Mani, Sridhar
机构：
来源：
JAMA NETWORK OPEN | 2024年 / 7卷 / 08期
关键词：
D O I：
10.1001/jamanetworkopen.2024.33744
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 35 条
  • [31] Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis (vol 73, 155, 2024)
    Chen, Yueying
    Han, Hedong
    Cheng, Jing
    Cheng, Qinpei
    Zhu, Suhua
    Zhan, Ping
    Liu, Hongbing
    Song, Yong
    Lv, Tangfeng
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (12)
  • [32] Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer (vol 24, pg 20, 2013)
    Soria, J. C.
    ANNALS OF ONCOLOGY, 2013, 24 (04) : 1133 - 1133
  • [33] Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trials
    Gu, Yunpeng
    Sun, Lei
    He, Yining
    Yang, Luping
    Deng, Chaohua
    Zhou, Run
    Kong, Tingting
    Zhang, Wei
    Chen, Yutong
    Li, Jie
    Shi, Junping
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2023, 17 (03) : 273 - 282
  • [34] Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients A network meta-analysis based on cardiovascular or renal outcome trials
    Duan, Xue-Yan
    Liu, Shu-Yan
    Yin, Dao-Gen
    MEDICINE, 2021, 100 (30) : E26431
  • [35] The impact on overall survival (OS) of first-line gefitinib (G) and erlotinib (E) and of clinical factors in advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor mutations (EGFR mut) based on meta-analysis of 1,231 patients (pts) enrolled in 6 major randomized trials.
    Lee, Chee
    Davies, Lucy Claire
    Wu, Yi-Long
    Mitsudomi, Tetsuya
    Inoue, Akira
    Rosell, Rafael
    Zhou, Caicun
    Nakagawa, Kazuhiko
    Throngprasert, Sumitra
    Fukuoka, Masahiro
    Gralla, Richard J.
    Gebski, Val
    Mok, Tony
    Yang, James Chih-Hsin
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
1234